Pfenex (PFNX) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts PFNX Hot Sheet
Join SI Premium – FREE
Pfenex (NYSE: PFNX) reported Q4 EPS of ($0.45), $0.21 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $5.47 million versus the consensus estimate of $3.23 million.
For earnings history and earnings-related data on Pfenex (PFNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- ImmuCell reports 46% sales increase in Q3 2026
- Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
